Journal article
Sustained Release of Hydrogen Sulfide (H 2 S) from Poly(Lactic Acid) Functionalized 4-Hydroxythiobenzamide Microparticles to Protect Against Oxidative Damage
Annals of biomedical engineering, Vol.47(8), pp.1691-1700
08/2019
DOI: 10.1007/s10439-019-02270-9
PMCID: PMC6650332
PMID: 31139973
Abstract
Hydrogen sulfide (H
S) has emerged as a gaseous mediator capable of exhibiting many beneficial properties including cytoprotection, anti-inflammation, and vasodilation. The study presented here provides characterization of a poly(lactic acid) polymer with a functionalized 4-hydroxythiobenzamide (PLA-4HTB) capable of extended H
S release. The polymer was used to fabricate microparticles that can be potentially loaded with a drug allowing for co-release of the drug and H
S. Microparticles with the average diameter of 500 ± 207 nm were fabricated and shown to release 77.0 ± 1.76 µM of H
S over 4 weeks (release of H
S from 1 mg of particles). To test for the antioxidant properties of the PLA-4HTB microparticles, human embryonic kidney 293 cells were first incubated with PLA-4HTB microparticles and then oxidative stress was induced using CoCl
. Particle suspensions of 1 mg/mL were shown to protect cells resulting in reactive oxygen species (ROS) levels of superoxide that were similar to that of the control group. The microparticles fabricated from the PLA-4HTB released H
S over a sustained period of weeks to months, while providing protection from ROS. The microparticles described in this article represent a new platform technology that could be used to prevent and treat diseases caused by oxidative damage.
Details
- Title: Subtitle
- Sustained Release of Hydrogen Sulfide (H 2 S) from Poly(Lactic Acid) Functionalized 4-Hydroxythiobenzamide Microparticles to Protect Against Oxidative Damage
- Creators
- Anh-Vu Do - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USARasheid Smith - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USAPhillip Tobias - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USADaniel Carlsen - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USAErica Pham - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USANed B Bowden - Department of Chemistry, College of Liberal Arts and Sciences, University of Iowa, Iowa, IA, USAAliasger K Salem - Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa, IA, USA. aliasger-salem@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Annals of biomedical engineering, Vol.47(8), pp.1691-1700
- DOI
- 10.1007/s10439-019-02270-9
- PMID
- 31139973
- PMCID
- PMC6650332
- NLM abbreviation
- Ann Biomed Eng
- ISSN
- 0090-6964
- eISSN
- 1573-9686
- Grant note
- P30 ES005605 / NIEHS NIH HHS 5P30CA086862 / National Institutes of Health P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 08/2019
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Chemistry; Dental Research; Chemical and Biochemical Engineering
- Record Identifier
- 9984216597702771
Metrics
10 Record Views